Cancer Biomarkers Market: Current Progress, Growth Drivers, challenges, and Future Development

-

 

Cancer Biomarkers is growing rapidly as an industry due to growing preference for wireless connectivity among healthcare providers, increasing incidence of cancer worldwide, increasing use of cancer biomarkers in drug discovery & development and increasing R&D on cancer biomarkers are among the other factors.

Currently, Cancer Biomarkers Market is growing at a Compound Annual Growth Rate (CAGR) of 17.7% to reach USD 28.2 billion by 2026. Market growth is driven by the increasing use of cancer biomarkers in drug discovery and development, increasing research on cancer biomarkers, technological advancements, and the increasing global incidence of cancer.

Request for assumptions & how numbers were triangulated.

https://www.marketsandmarkets.com/requestsampleNew.asp?id=202 

Market Growth Drivers

  • Rising technological advancements in the development of cancer biomarkers
  • Increasing incidence of cancer worldwide
  • Increasing use of cancer biomarkers in drug discovery & development

Market Growth Opportunities

  • Increased recognition of personalized medicine
  • Growing application areas of companion diagnostics
  • Emerging economies

Market Challenges 

  • Challenges associated with cancer biomarker validation.
  • Shortage of skilled professionals

Restraints

  • Technical issues related to sample collection and storage.
  • High capital investments and extensive timelines for the development of cancer biomarkers

The prominent players operating in the Cancer Biomarkers Market are. 

F. Hoffmann-La Roche Ltd. (Switzerland), Thermo Fisher Scientific, Inc. (US), QIAGEN N.V. (Netherlands), Illumina, Inc. (US), Bio-Rad Laboratories, Inc. (US), Abbott Laboratories (US), bioMérieux SA (US)

F. Hoffmann-La Roche Ltd. held the leading position in the cancer biomarkers market in 2020. La Roche focuses on innovation to maintain its market share. It invests a significant amount of its revenue in R&D activities for this purpose. These investments are used to develop new and innovative products. The company’s major share comes from the US. With its high R&D capabilities, excellent balance sheet, and asset quality, the company is expected to witness a higher growth rate in the forecast period.

Thermo Fisher Scientific, Inc. held the second position in the cancer biomarkers market. The company focuses on innovation to maintain its market share. It invests a significant amount of its revenue in R&D activities for this purpose. These investments are used to develop new and innovative products. The company’s major share comes from the US. With its high R&D capabilities, excellent balance sheet, and asset quality, the company is expected to witness a higher growth rate in the forecast period.

Download an Illustrative Overview:

https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=202 

Competitive leadership mapping has been updated considering recent developments in the company evaluation matrix and company profiles section of the current edition of the market report.

Recent Developments

  • In April 2021, F. Hoffmann-La Roche Ltd. (Switzerland), Launched Elecsys Anti-p53 immunoassay to aid the diagnosis of various cancer types.
  • In December 2020, Thermo Fisher Scientific (US) received FDA approves NGS-based companion diagnostic for EGFR Exon20 insertion mutant non-small cell lung cancer tumor tissue.
  • In April 2020, Qiagen N.V. (Netherlands) Launched therascreen BRAF test as a companion diagnostic to a BRAFTOVI (encorafenib) based regimen in metastatic colorectal cancer.

Content Source: 

https://www.prnewswire.com/news-releases/cancer-biomarkers-market-worth-28-2-billion-by-2026--exclusive-report-by-marketsandmarkets-301505629.html

https://www.globenewswire.com/en/news-release/2022/05/31/2453442/0/en/Cancer-Biomarkers-Market-worth-28-2-billion-by-2026-Report-by-MarketsandMarkets.html

Comments

Post a Comment

Popular posts from this blog

Future of Remote Patient Monitoring Industry: Impact of Remote Patient Monitoring on Healthcare

-
Remote patient monitoring is a type of telemedicine technology that enables healthcare providers to monitor their patients’ health remotely. This technology utilizes remote devices that are placed in the patient’s home or worn by the patient to collect medical data such as vital signs and other medical information.  This medical data is then transmitted to the doctor or healthcare provider to help them make better decisions regarding the patient’s care. RPM can be used to monitor a variety of conditions including chronic diseases, mental health issues, and post-operative care. It can also be used to support elderly individuals and those with disabilities. RPM has the potential to improve patient outcomes and reduce healthcare costs by enabling healthcare providers to monitor their patients’ health more effectively. Benefits of Remote Patient Monitoring 1. Increased Patient Engagement: Remote patient monitoring systems provide patients with a convenient way to stay engaged in their ow
Read more

Sinus Dilation Devices Market Size And Share Report, 2027

-
The sinus dilation devices market is on track for significant growth in the coming years, projected to reach USD 3.8 billion by 2027, up from USD 2.8 billion in 2022. This represents a compound annual growth rate (CAGR) of 6.6% during the forecast period. The market's expansion is largely driven by the increasing availability of reimbursements and rising cases of chronic sinusitis. However, the market faces challenges due to the availability of non-surgical treatments for chronic sinusitis and a shortage of skilled ENT surgeons. Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=64349810 Key Market Drivers Increasing Availability of Reimbursements: The growing availability of reimbursements for sinus dilation procedures is making them more accessible to patients, thereby driving demand for sinus dilation devices. Rising Incidence of Chronic Sinusitis: The prevalence of chronic sinusitis is on the rise globally, leading to an increase in d
Read more

Stable Isotope Labeled Compounds Market Growth: Trends and Opportunities

-
The global stable isotope labeled compounds market size is projected to reach USD 312 million by 2024 from USD 269 million in 2019, at a CAGR of 3.0% between 2019 and 2024. The growth of this market is driven majorly by the increase in research activities in the pharmaceutical and biotechnology sector, the rising prevalence of cancer, and rising proteomics research. However, the high cost of stable isotope-labeled compounds is expected to restrain the growth of this market during the forecast period. Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=53034199 The H-2 labeled compounds segment accounted for the largest share of the stable isotope labeled compounds market. Based on type, the stable isotope labeled compounds industry is segmented into C-13, N-15, O-18, H-2 (deuterium), and other isotopes. The H-2 labeled compounds segment accounted for the largest share of the stable isotope-labeled compounds market in 2019. The large share of this
Read more